《中医药监督工作指南(测试版)》印发

2018-02-27 朱蕗鋆 中国中医

为进一步贯彻落实党的十九大、全国卫生与健康大会精神,全面推进依法治国,加强事中事后监管,着力推进中医药监督执法工作开展,为各地区开展中医药监督工作提供指导依据,制定本方案:

为进一步贯彻落实党的十九大、全国卫生与健康大会精神,全面推进依法治国,加强事中事后监管,着力推进中医药监督执法工作开展,为各地区开展中医药监督工作提供指导依据,制定本方案:

一、总体思路

(一)指导思想

以习近平新时代中国特色社会主义思想为指导,全面贯彻党的十九大精神和习近平总书记发展中医药的新思想新论断新要求,坚持依法治国基本方略,认真落实简政放权、放管结合、优化服务有关要求,积极推进基层中医药监督工作标准化规范化发展,全面提升中医药监督执法能力和水平。

(二)基本原则

统筹兼顾,扎实推进;严格要求,注重实效;知行合一,求真务实;紧跟进度,全面落实。

(三)目标任务

1.检验《中医药监督工作指南(测试版)》(以下简称《指南》)的科学性、规范性、指导性,汲取好的经验和做法,进一步修改完善《指南》,为今后在全国范围推行《指南》奠定良好基础。

2.加快推进中医药监督执法工作发展,明确中医药监督执法职责和任务,建立健全工作制度,提升监督执法能力。

3.完善中医药监督执法基础理论,加强中医药监督执法的规范化建设,发挥示范引导作用。

二、试点地区

天津、辽宁、江苏、海南、四川、甘肃等6省市。

三、试点内容

(一)各省(市)明确试点监督机构和联系人。

(二)组织开展《指南》试点方案的学习、培训工作。

(三)开展试点工作,及时收集在指南试用过程中遇到的问题。

(四)定期组织召开试点工作研究及推进会议,并进行督导调研。

(五)试点工作结束后按时上报试点工作总结及相关材料。

四、工作安排

(一)国家组织开展全国试点启动暨培训工作。(2月)

(二)各省(市)启动试点,制订本省(市)试点工作实施方案,开展相关培训。(3月)

(三)试点地区根据各省(市)试点工作实施方案,认真组织实施。(4-9月)

(四)试点省(市)上报工作总结。(10月)

(五)进行全国试点工作总结。(11月)

五、工作要求

(一)精心组织,周密部署。

各地要充分认识此次试点工作的重要性,加强组织领导,制定具体实施方案,明确工作内容、工作要求和时间进度,定期召开试点工作会议,及时总结试点中遇到的问题,确保试点工作扎实有序开展。各省(市)监督机构要成立领导小组,确定组长和具体负责同志,各试点省(市)至少选择2个市、6个县(区)参与此次试点工作,有条件的省(市)可全省(市)参加试点工作,并于2月28日前上报试点地区基本情况汇总表(附表1)。国家将给予试点省(市)经费补助用于试点工作开展并且择机对部分试点地区进行督导调研。

(二)理清思路,明确任务。

各地要通过此次试点工作,进一步理清中医药监督执法工作整体思路,明确工作职责和监督内容,掌握监督检查的方式、方法和要求。各地在开展此项工作中要本着“带着问题”、“寻找问题”的思路去试用,同时要提出解决问题的意见和建议,为进一步完善《指南》提供参考依据。各地要根据试点时间的要求,及时完成试点工作总结,于10月31日前上报总结及汇总表(附表2、3、4),总结中要体现试点工作实施情况、取得的成绩、遇到的问题、提出的修改建议等内容。

(三)加强培训,注重实效。

各地要结合此次试点工作,全面推进本地区中医药监督执法工作,提升中医药监督执法工作效能。各地应在建立健全中医药监督队伍和提升中医药监督执法能力上下功夫,以此次试点工作为契机,加强中医药监督执法实践培训工作,增强监督执法人员对中医药监督执法的认识,掌握监督检查内容、方式、方法,提升案件查办能力,规范中医药医疗服务市场秩序,保障人民群众就医安全和中医药事业健康发展。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1683929, encodeId=f18016839291b, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Fri Jan 18 02:22:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409373, encodeId=e1fe14093e346, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 01 09:22:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291474, encodeId=a2c52914e4ff, content=学习了.受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Feb 27 20:06:15 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291455, encodeId=c2c92914558f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Feb 27 19:05:48 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291449, encodeId=a67d291449ea, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Feb 27 18:52:16 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2019-01-18 zxl738
  2. [GetPortalCommentsPageByObjectIdResponse(id=1683929, encodeId=f18016839291b, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Fri Jan 18 02:22:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409373, encodeId=e1fe14093e346, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 01 09:22:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291474, encodeId=a2c52914e4ff, content=学习了.受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Feb 27 20:06:15 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291455, encodeId=c2c92914558f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Feb 27 19:05:48 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291449, encodeId=a67d291449ea, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Feb 27 18:52:16 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-03-01 hb2008ye
  3. [GetPortalCommentsPageByObjectIdResponse(id=1683929, encodeId=f18016839291b, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Fri Jan 18 02:22:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409373, encodeId=e1fe14093e346, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 01 09:22:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291474, encodeId=a2c52914e4ff, content=学习了.受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Feb 27 20:06:15 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291455, encodeId=c2c92914558f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Feb 27 19:05:48 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291449, encodeId=a67d291449ea, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Feb 27 18:52:16 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-02-27 1e0f8808m18(暂无匿称)

    学习了.受益匪浅.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1683929, encodeId=f18016839291b, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Fri Jan 18 02:22:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409373, encodeId=e1fe14093e346, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 01 09:22:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291474, encodeId=a2c52914e4ff, content=学习了.受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Feb 27 20:06:15 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291455, encodeId=c2c92914558f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Feb 27 19:05:48 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291449, encodeId=a67d291449ea, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Feb 27 18:52:16 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-02-27 131****1460

    学习了受益匪浅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1683929, encodeId=f18016839291b, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Fri Jan 18 02:22:00 CST 2019, time=2019-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409373, encodeId=e1fe14093e346, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Thu Mar 01 09:22:00 CST 2018, time=2018-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291474, encodeId=a2c52914e4ff, content=学习了.受益匪浅., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Tue Feb 27 20:06:15 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291455, encodeId=c2c92914558f, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Tue Feb 27 19:05:48 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=291449, encodeId=a67d291449ea, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Feb 27 18:52:16 CST 2018, time=2018-02-27, status=1, ipAttribution=)]
    2018-02-27 清风拂面

    谢谢分享学习

    0

相关资讯

刘延东:为建设健康中国作出中医药贡献

2月3日,国务院副总理刘延东调研重庆市中医院,强调要深入学习贯彻习近平新时代中国特色社会主义思想和党的十九大精神,充分发挥中医药在防病治病中的独特优势,为建设健康中国、让群众享有更多获得感幸福感作出中医药独特贡献。

河南省2018年中医药工作会议:2030年全面建成中医药强省

日前,河南省召开2018年中医药工作会议,研究部署2018年重点工作。会议指出,着力完善中医医疗服务体系,推进中医药强省战略,要明确2020年、2030年两个阶段性目标,让中医药五大资源优势的潜力竞相迸发,让中医药强省的蓝图早日转化为中原百姓的健康福祉。

吉林省中医药工作会议明确2018年工作主线,继承好发展好利用好中医药

2018年吉林省中医药工作会议召开。会议传达了全国中医药工作会议精神,部署2018年重点任务。

全国政协委员研讨分级诊疗与多点执业:要给予中医药高度重视

人民政协报社邀请多名医药卫生界全国政协委员及相关专家,以“学习十九大精神·建设健康中国——落实分级诊疗与多点执业”为主题召开研讨会。多名委员提出,应注重发挥中医药在推动建立分级诊疗制度中的优势。

加强中医药传承创新,建优扶强一批中医机构

国务院副总理刘延东近日在重庆调研时强调,要深入学习贯彻习近平新时代中国特色社会主义思想和党的十九大精神,坚定实施科教兴国战略、人才强国战略、创新驱动发展战略、健康中国战略,推动教科文卫等社会事业发展迈上新台阶,更好满足人民对美好生活的需要,为决胜全面建成小康社会作出新贡献。

深化改革是中医药工作**主题

2018年北京中医药工作会议召开。会议总结了2017年首都中医药改革发展的工作情况及十八大以来取得的成就,研究部署2018年中医药工作的重点任务,并提出深化改革是2018年北京市中医药工作的第一主题,要加快推进实施区域发展战略,加快推进“十三五”规划实施。